Published in J Infect Dis on January 01, 1992
The Mycobacterium avium complex. Clin Microbiol Rev (1993) 7.67
Mycobacterium avium subsp. paratuberculosis in Veterinary Medicine. Clin Microbiol Rev (2001) 3.58
Interaction of Mycobacterium avium with environmental amoebae enhances virulence. Infect Immun (1997) 3.14
Intracellular growth in Acanthamoeba castellanii affects monocyte entry mechanisms and enhances virulence of Legionella pneumophila. Infect Immun (1999) 1.93
Alcohol use accelerates HIV disease progression. AIDS Res Hum Retroviruses (2010) 1.85
Microbial infections, immunomodulation, and drugs of abuse. Clin Microbiol Rev (2003) 1.71
Susceptibility of beige mice to Mycobacterium avium: role of neutrophils. Infect Immun (1995) 1.63
Legionella pneumophila entry gene rtxA is involved in virulence. Infect Immun (2001) 1.52
Factors affecting invasion of HT-29 and HEp-2 epithelial cells by organisms of the Mycobacterium avium complex. Infect Immun (1994) 1.46
Genetic and phenotypic differences between Legionella pneumophila strains. J Clin Microbiol (2002) 1.41
Mycobacterium avium grown in Acanthamoeba castellanii is protected from the effects of antimicrobials. Antimicrob Agents Chemother (2000) 1.29
Exposure to low oxygen tension and increased osmolarity enhance the ability of Mycobacterium avium to enter intestinal epithelial (HT-29) cells. Infect Immun (1997) 1.17
Outer membrane protein D15 is conserved among Haemophilus influenzae species and may represent a universal protective antigen against invasive disease. Infect Immun (1997) 1.17
Beige mouse model for Mycobacterium avium complex disease. Antimicrob Agents Chemother (1995) 1.13
Differential gene expression in mononuclear phagocytes infected with pathogenic and non-pathogenic mycobacteria. Clin Exp Immunol (2004) 1.10
Alcohol exacerbates murine pulmonary tuberculosis. Infect Immun (2004) 1.08
Mycobacterium avium invades the intestinal mucosa primarily by interacting with enterocytes. Infect Immun (2001) 1.04
Host response to nontuberculous mycobacterial infections of current clinical importance. Infect Immun (2014) 1.03
Clarithromycin, dapsone, and a combination of both used to treat or prevent disseminated Mycobacterium avium infection in beige mice. Antimicrob Agents Chemother (1994) 1.02
Identification of Mycobacterium avium genes that affect invasion of the intestinal epithelium. Infect Immun (2005) 0.95
CD4+ T cells but Not CD8+ or gammadelta+ lymphocytes are required for host protection against Mycobacterium avium infection and dissemination through the intestinal route. Infect Immun (2005) 0.95
Response to stimulation with recombinant cytokines and synthesis of cytokines by murine intestinal macrophages infected with the Mycobacterium avium complex. Infect Immun (1995) 0.94
Peyer's patch-deficient mice demonstrate that Mycobacterium avium subsp. paratuberculosis translocates across the mucosal barrier via both M cells and enterocytes but has inefficient dissemination. Infect Immun (2010) 0.91
Invasion of the brain and chronic central nervous system infection after systemic Mycobacterium avium complex infection in mice. Infect Immun (2000) 0.91
Identification of virulence determinants of Mycobacterium avium that impact on the ability to resist host killing mechanisms. J Med Microbiol (2010) 0.89
Identification and differentiation of Mycobacterium avium and M. intracellulare by PCR. J Clin Microbiol (1996) 0.88
Mycobacterium avium infection of epithelial cells results in inhibition or delay in the release of interleukin-8 and RANTES. Infect Immun (1999) 0.87
Rodent models of alcoholic liver disease. Int J Exp Pathol (1994) 0.76
Prevalence of Mycobacterium avium in slaughter pigs based on serological monitoring results and bacteriological validation. Int J Environ Res Public Health (2013) 0.75
Natural history of cervical human papillomavirus infection in young women: a longitudinal cohort study. Lancet (2001) 7.31
Differences in B cell growth phenotype reflect novel patterns of Epstein-Barr virus latent gene expression in Burkitt's lymphoma cells. EMBO J (1987) 6.26
Expression of Epstein-Barr virus latent gene products in tumour cells of Hodgkin's disease. Lancet (1991) 4.76
Mycobacterial infections in AIDS patients, with an emphasis on the Mycobacterium avium complex. Rev Infect Dis (1987) 4.54
Tumor necrosis factor, alone or in combination with IL-2, but not IFN-gamma, is associated with macrophage killing of Mycobacterium avium complex. J Immunol (1988) 4.47
Severe candidal infections: clinical perspective, immune defense mechanisms, and current concepts of therapy. Ann Intern Med (1978) 4.15
Epstein-Barr virus latency in blood mononuclear cells: analysis of viral gene transcription during primary infection and in the carrier state. J Virol (1994) 4.08
Simple method for elimination of aminoglycosides from serum to permit bioassay of other antimicrobial agents. Antimicrob Agents Chemother (1977) 3.91
Aspergillosis complicating neoplastic disease. Am J Med (1973) 3.80
Influence of the Epstein-Barr virus nuclear antigen EBNA 2 on the growth phenotype of virus-transformed B cells. J Virol (1987) 3.53
Epstein-Barr virus latent gene transcription in nasopharyngeal carcinoma cells: coexpression of EBNA1, LMP1, and LMP2 transcripts. J Virol (1992) 3.41
Monoclonal antibodies to the latent membrane protein of Epstein-Barr virus reveal heterogeneity of the protein and inducible expression in virus-transformed cells. J Gen Virol (1987) 3.28
Human immunity to Pseudomonas aeruginosa. I. In-vitro interaction of bacteria, polymorphonuclear leukocytes, and serum factors. J Infect Dis (1972) 3.28
Determination of in vitro susceptibility of Mycobacterium avium complex isolates to antimycobacterial agents by various methods. Antimicrob Agents Chemother (1987) 3.06
Hemagglutination typing of Escherichia coli: definition of seven hemagglutination types. J Clin Microbiol (1980) 3.03
Molecular evolution of the metaplasia-dysplasia-adenocarcinoma sequence in the esophagus. Am J Pathol (1999) 2.88
Activity of five aminoglycoside antibiotics in vitro against gram-negative bacilli and Staphylococcus aureus. Antimicrob Agents Chemother (1973) 2.85
Hemolysin and K antigens in relation to serotype and hemagglutination type of Escherichia coli isolated from extraintestinal infections. J Clin Microbiol (1981) 2.82
In vitro studies of piperacilin, a new semisynthetic penicillin. Antimicrob Agents Chemother (1978) 2.82
Epstein-Barr virus latent membrane protein inhibits human epithelial cell differentiation. Nature (1990) 2.72
Epstein-Barr virus infection and replication in a human epithelial cell system. Nature (1992) 2.62
Epstein-Barr virus persistence and virus-associated tumours. Lancet (1994) 2.60
Tobramycin (nebramycin factor 6): in vitro activity against Pseudomonas aeruginosa. Appl Microbiol (1971) 2.60
Epstein-Barr virus and Hodgkin's disease: transcriptional analysis of virus latency in the malignant cells. J Exp Med (1993) 2.56
Confirmation of the beige mouse model for study of disseminated infection with Mycobacterium avium complex. J Infect Dis (1986) 2.56
Nontuberculous mycobacterial infections: a clinical review. Infection (2004) 2.56
Septicemia due to Aeromonas hydrophila: clinical and immunologic aspects. J Infect Dis (1973) 2.55
Protective activity of antibodies to exotoxin A and lipopolysaccharide at the onset of Pseudomonas aeruginosa septicemia in man. J Clin Invest (1979) 2.50
Treatment of disseminated Mycobacterium avium complex infection in AIDS with amikacin, ethambutol, rifampin, and ciprofloxacin. California Collaborative Treatment Group. Ann Intern Med (1990) 2.45
Comparison of methods for assessing in vitro antibiotic synergism against Pseudomonas and Serratia. J Lab Clin Med (1975) 2.41
Radioimmunoassay, acetylating radio-enzymatic assay, and microbioassay of gentamicin: a comparative study. J Lab Clin Med (1975) 2.30
Distinction between Epstein-Barr virus type A (EBNA 2A) and type B (EBNA 2B) isolates extends to the EBNA 3 family of nuclear proteins. J Virol (1989) 2.23
Nocardia asteroides infection complicating neoplastic disease. Am J Med (1971) 2.23
Comparative in vitro activity of moxalactam, cefotaxime, cefoperazone, piperacillin, and aminoglycosides against gram-negative bacilli. Antimicrob Agents Chemother (1980) 2.23
Activation of the cJun N-terminal kinase (JNK) pathway by the Epstein-Barr virus-encoded latent membrane protein 1 (LMP1). Oncogene (1998) 2.22
Epstein-Barr virus (EBV)-associated lymphoproliferative disease in the SCID mouse model: implications for the pathogenesis of EBV-positive lymphomas in man. J Exp Med (1991) 2.20
A short 5' flanking region containing conserved sequences is required for silkworm alanine tRNA gene activity. Proc Natl Acad Sci U S A (1983) 2.19
Activation of the p38 mitogen-activated protein kinase pathway by Epstein-Barr virus-encoded latent membrane protein 1 coregulates interleukin-6 and interleukin-8 production. J Biol Chem (1999) 2.17
Azithromycin for treatment of Mycobacterium avium-intracellulare complex infection in patients with AIDS. Lancet (1991) 2.15
1997 guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. Infectious Diseases Society of America. Clin Infect Dis (1997) 2.14
Piperacillin therapy for serious bacterial infections. Am J Med (1980) 2.14
Trimethoprim-sulfamethoxazole for the treatment of Pneumocystis carinii pneumonia. Ann Intern Med (1980) 2.11
A simultaneous outbreak of meningococcal and influenza infections. N Engl J Med (1972) 2.11
Interaction of Mycobacterium avium complex with human macrophages: roles of membrane receptors and serum proteins. Infect Immun (1991) 1.97
Treatment of experimental disseminated Mycobacterium avium complex infection in mice with recombinant IL-2 and tumor necrosis factor. J Immunol (1989) 1.92
Gram-negative rod bacteremia: microbiologic, immunologic, and therapeutic considerations. Ann Intern Med (1977) 1.90
Antimicrobial synergism in the therapy of gram-negative rod bacteremia. Chemotherapy (1978) 1.88
Transcripts from the Epstein-Barr virus BamHI A fragment are detectable in all three forms of virus latency. J Virol (1993) 1.88
Epstein-Barr virus receptors on human pharyngeal epithelia. Lancet (1986) 1.88
Comparative efficacy and toxicity of amikacin/carbenicillin versus gentamicin/carbenicillin in leukopenic patients: a randomized prospective trail. Am J Med (1977) 1.86
CD40-induced growth inhibition in epithelial cells is mimicked by Epstein-Barr Virus-encoded LMP1: involvement of TRAF3 as a common mediator. Oncogene (1996) 1.85
LMP1 structure and signal transduction. Semin Cancer Biol (2001) 1.85
Functional role of antibody against "core" glycolipid of Enterobacteriaceae. J Clin Invest (1975) 1.80
Epstein-Barr virus-encoded latent membrane protein 1 activates the JNK pathway through its extreme C terminus via a mechanism involving TRADD and TRAF2. J Virol (1999) 1.76
Infectious complications of neoplastic disease. Med Clin North Am (1971) 1.75
Infectious complications of human bone marrow transplantation. Medicine (Baltimore) (1979) 1.74
Epstein-Barr virus-encoded LMP1 and CD40 mediate IL-6 production in epithelial cells via an NF-kappaB pathway involving TNF receptor-associated factors. Oncogene (1997) 1.74
Therapeutic and epidemiologic recommendations to reduce the spread of type-I beta-lactamase resistance. Diagn Microbiol Infect Dis (1992) 1.74
Human epithelial cell expression of an Epstein-Barr virus receptor. J Gen Virol (1987) 1.73
Pseudomonas aeruginosa vaccine in cancer patients. Ann Intern Med (1973) 1.73
The role of exotoxins in the pathogenesis of Pseudomonas aeruginosa infections. J Infect Dis (1980) 1.73
Epstein-Barr virus (EBV) infection in infectious mononucleosis: virus latency, replication and phenotype of EBV-infected cells. J Pathol (1997) 1.72
Human immunity to Pseudomonas aeruginosa. II. Relationship between heat-stable opsonins and type-specific lipopolysaccharides. J Infect Dis (1972) 1.71
Epstein-Barr virus infection in oral hairy leukoplakia: virus replication in the absence of a detectable latent phase. J Gen Virol (1991) 1.70
Activity of ciprofloxacin and other fluorinated quinolones against mycobacteria. Am J Med (1987) 1.69
Clinical and metabolic efficacy of glutamine-supplemented parenteral nutrition after bone marrow transplantation. A randomized, double-blind, controlled study. Ann Intern Med (1992) 1.68
Quantitative granulocyte chemiluminescence in the rapid detection of impaired opsonization of Escherichia coli. Infect Immun (1977) 1.66
Improved acetylating radioenzymatic assay of amikacin, tobramycin, and sisomicin in serum. Antimicrob Agents Chemother (1975) 1.63
Simultaneous antibiotic levels in "breakthrough" gram-negative rod bacteremia. Am J Med (1976) 1.62
Recombinant granulocyte-macrophage colony-stimulating factor activates human macrophages to inhibit growth or kill Mycobacterium avium complex. J Leukoc Biol (1990) 1.62
A large region controls tRNA gene transcription. J Mol Biol (1985) 1.61
A new treatment for patients with short-bowel syndrome. Growth hormone, glutamine, and a modified diet. Ann Surg (1995) 1.61
In vitro studies with netilmicin compared with amikacin, gentamicin, and tobramycin. Antimicrob Agents Chemother (1977) 1.60
HLA A2.1-restricted cytotoxic T cells recognizing a range of Epstein-Barr virus isolates through a defined epitope in latent membrane protein LMP2. J Virol (1993) 1.58
Activation of the small GTPase Cdc42 by the inflammatory cytokines TNF(alpha) and IL-1, and by the Epstein-Barr virus transforming protein LMP1. J Cell Sci (1999) 1.57
Nosocomial infections in the immunocompromised adult. Am J Med (1981) 1.56
Evaluation of new anti-infective drugs for the treatment of febrile episodes in neutropenic patients. Infectious Diseases Society of America and the Food and Drug Administration. Clin Infect Dis (1992) 1.56
Trimethoprim-sulfamethoxazole in the treatment of adults with pneumonia due to Pneumocystis carinii. Rev Infect Dis (1982) 1.55
Activities of amikacin, roxithromycin, and azithromycin alone or in combination with tumor necrosis factor against Mycobacterium avium complex. Antimicrob Agents Chemother (1988) 1.54
Restricted complement activation by Escherichia coli with the K-1 capsular serotype: a possible role in pathogenicity. J Immunol (1978) 1.54
Three transcriptionally distinct forms of Epstein-Barr virus latency in somatic cell hybrids: cell phenotype dependence of virus promoter usage. Virology (1992) 1.53
Moxalactam therapy for bacterial infections. Arch Intern Med (1981) 1.53
Amikacin, ciprofloxacin, and imipenem treatment for disseminated Mycobacterium avium complex infection of beige mice. Antimicrob Agents Chemother (1989) 1.52
Patterns of Epstein-Barr virus infection in non-neoplastic lymphoid tissue. Blood (1992) 1.51
P53 overexpression and Epstein-Barr virus infection in undifferentiated and squamous cell nasopharyngeal carcinomas. J Pathol (1993) 1.51
Intracellular killing of Mycobacterium avium complex by rifapentine and liposome-encapsulated amikacin. J Infect Dis (1987) 1.49
The properties of a new polymerase III transcription factor reveal that transcription complexes can assemble by more than one pathway. EMBO J (1987) 1.49
Non-Hodgkin's lymphoma, coeliac disease, and Epstein-Barr virus: a study of 13 cases of enteropathy-associated T- and B-cell lymphoma. J Pathol (1995) 1.49
In vitro activity of BMY-28142 in comparison with those of other beta-lactam antimicrobial agents. Antimicrob Agents Chemother (1985) 1.49
Tetanus in the United States (1965-1966):epidemiologic and clinical features. N Engl J Med (1969) 1.48
Bcl-2 expression identifies patients with advanced bladder cancer treated by radiotherapy who benefit from neoadjuvant chemotherapy. BJU Int (2000) 1.47
Tularemia epidemia: Vermont, 1968. Forty-seven cases linked to contact with muskrats. N Engl J Med (1969) 1.47
Factors affecting invasion of HT-29 and HEp-2 epithelial cells by organisms of the Mycobacterium avium complex. Infect Immun (1994) 1.46
Distribution and phenotype of Epstein-Barr virus-harboring cells in Hodgkin's disease. Blood (1992) 1.45
Immunohistochemical detection of the Epstein-Barr virus-encoded latent membrane protein 2A in Hodgkin's disease and infectious mononucleosis. Blood (1997) 1.45
In vitro and in vivo activity of azithromycin (CP 62,993) against the Mycobacterium avium complex. J Infect Dis (1989) 1.44
Epstein-Barr virus in inflammatory diseases of the liver and liver allografts: an in situ hybridization study. Hepatology (1994) 1.43